Phosphatidylcholine

What phosphatidylcholine is

Phosphatidylcholine is a phospholipid made of glycerol, two fatty acids, a phosphate group and choline. It is a basic building block of cell membranes and the main component of lecithin, which is authorized as the additive E 322. In food, it is found in egg yolk and soy, among others; two hard-boiled eggs served as the phosphatidylcholine test meal in a large study (Tang 2013).

As supplements, there are lecithin, enriched phosphatidylcholine and so-called essential phospholipids (EPL) or polyenylphosphatidylcholine (PPC) with a high proportion of polyunsaturated fatty acids. Related choline sources are alpha-GPC and citicoline. In the BK-Score, human evidence stands at 6 out of 10 points. This axis rates the state of knowledge, not the substance: well studied here mainly means that several large studies found no benefit.

How it is supposed to work

Two routes are named. First, phosphatidylcholine supplies choline, which the body needs for membranes and as a building block of the messenger substance acetylcholine. On this basis, the EU has authorized three health claims for choline: normal lipid metabolism, normal homocysteine metabolism and maintenance of normal liver function. Second, polyenylphosphatidylcholine prevented alcohol-induced liver cirrhosis in animal experiments; that was the basis of the large liver study in alcoholics (Lieber 2003).

A third route is more of a risk: gut bacteria convert the choline part into a precursor from which TMAO is formed. Tang 2013 showed that this conversion depends on the gut flora; after broad-spectrum antibiotics, TMAO in the blood was markedly suppressed and reappeared after they were stopped.

What the studies show

Fatty liver: liver fat value lowered

Stefan 2026 randomized 193 patients with fatty liver (MASLD) and additionally type 2 diabetes, dyslipidemia or overweight to essential phospholipids or placebo, each in addition to standard treatment; 165 were analyzed. More than three quarters were obese. The primary endpoint, the change in the liver fat value CAP after 6 months, was met (p = 0.027); the effect appeared after just 3 months and persisted until 3 months after the end of treatment. In addition, HbA1c and the fatigue score in the quality-of-life questionnaire fell; overall quality of life improved only numerically. CAP is an ultrasound measurement of liver fat, a surrogate marker; progression of liver disease was not the primary endpoint.

Alcoholic liver fibrosis: no difference

Lieber 2003 randomized 789 heavy drinkers with early liver fibrosis at 20 hospitals of the US Department of Veterans Affairs to polyenylphosphatidylcholine or placebo. After two years, a second liver biopsy was available from 412 patients. Fibrosis progressed about equally often under the product and placebo, in 22.8 versus 20.0 percent. Participants reduced their drinking on average from 16 to about 2.5 drinks per day; in subgroups there was a trend toward better liver values under the product.

Ulcerative colitis: early hope, large study stopped

Smaller studies with delayed-release phosphatidylcholine had been positive. Dignass 2024 then tested the formulation LT-02 in two large double-blind studies in mild to moderate ulcerative colitis. The induction study was stopped for futility after an interim analysis: in 466 patients, deep remission after 12 weeks was 13.5 percent under placebo and 14.2 and 9.7 percent under the two LT-02 doses. In the maintenance study with 150 patients, remission rates after 48 weeks did not differ significantly (49.3 percent LT-02, 50.0 percent mesalazine, 43.2 percent placebo).

Dementia: no clear benefit

A 2003 Cochrane review by Higgins and Flicker pooled 12 randomized studies on lecithin in Alzheimer’s disease, Parkinson’s dementia and subjective memory problems. In Alzheimer’s disease and Parkinson’s dementia, no study reported a clear clinical benefit. A single study in people with subjective memory problems was clearly positive. The authors conclude that the data do not support use in dementia; they cannot rule out a moderate effect.

Where the data stop

• The liver beyond liver fat. The positive finding concerns a measurement of liver fat. That fibrosis, cirrhosis or complications can be prevented has not been shown; in alcoholics, the product did not slow fibrosis.
• Brain and memory. For dementia, the Cochrane review found no clear benefit. The single positive finding in subjective memory problems is an isolated finding.
• Ulcerative colitis. After the large induction study was stopped, the benefit is open; a possible signal in maintenance therapy would first have to be confirmed in a sufficiently large study.
• Cardiovascular. Whether regular phosphatidylcholine capsules change heart risk via TMAO has not been clarified; the TMAO data come from observations.

Status, approval and legal

Phosphatidylcholine and lecithin are foods or food ingredients; lecithin is authorized as the additive E 322. For choline, the EU authorized three health claims with Regulation (EU) No 432/2012: choline contributes to normal lipid metabolism, to normal homocysteine metabolism and to the maintenance of normal liver function. The condition is at least 82.5 mg of choline per 100 g, 100 ml or portion. Claims on the brain and memory are not among them.

The 2026 fatty liver study was a phase 4 study, that is, a study with a product already approved as a medicine. Advertising for food supplements with phosphatidylcholine may not rely on it: disease-related claims are not permitted for foods.

Safety

In the large studies, phosphatidylcholine was well tolerated: in the colitis study over up to 48 weeks and in the fatty liver study over 6 months, no safety problems emerged. The significance of TMAO is open. In a cohort of 4007 patients who underwent a scheduled cardiac catheterization, people in the highest quarter of TMAO levels had a markedly higher risk of heart attack, stroke or death within three years than those in the lowest quarter, with a hazard ratio of 2.54 (Tang 2013). That is an association, not proof that phosphatidylcholine capsules increase heart risk.

In the BK-Score, safety data stand at 7 out of 10 points; this axis measures how well safety has been studied, not how safe the substance is. This text is information and does not replace medical advice.

Sources

• Stefan N et al., Liver Int 2026 – essential phospholipids in fatty liver (MASLD), randomized phase 4 study with 193 patients
• Lieber CS et al., Alcohol Clin Exp Res 2003 – polyenylphosphatidylcholine in alcoholic liver disease, VA study with 789 patients
• Dignass A et al., Clin Gastroenterol Hepatol 2024 – delayed-release phosphatidylcholine (LT-02) in ulcerative colitis, two double-blind RCTs
• Higgins JP, Flicker L, Cochrane Database Syst Rev 2003 – lecithin for dementia and cognitive impairment
• Tang WH et al., N Engl J Med 2013 – breakdown of phosphatidylcholine by gut bacteria, TMAO and cardiovascular risk
• EFSA NDA Panel 2016 – dietary reference values for choline (EFSA Journal 14(8):4484)
• Regulation (EU) No 432/2012 – authorized health claims, including three on choline
• European Commission, food additives database – E 322 lecithins